2-piperidone has been researched along with Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bijou, F; Bouabdallah, R; Chen, T; Chiappella, A; Doorduijn, JK; Hagner, PR; Hege, K; Kersten, MJ; Klein, C; Mendez, C; Michot, JM; Mosulen, S; Nikolova, Z; Pourdehnad, M; Ribrag, V; Salles, G; Sarmiento, R; Uttamsingh, S; Vitolo, U; Zinzani, PL | 1 |
| Abbiati, RA; Carrancio, S; Kasibhatla, S; Loos, R; McConnell, M; Pierce, DW; Pourdehnad, M; Ratushny, AV; Santini, CC; Trotter, MWB | 1 |
1 trial(s) available for 2-piperidone and Neutropenia
| Article | Year |
|---|---|
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Half-Life; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Piperidones; Quinazolinones; Recurrence; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2020 |
1 other study(ies) available for 2-piperidone and Neutropenia
| Article | Year |
|---|---|
Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
Topics: Antineoplastic Agents; Biological Variation, Population; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Models, Biological; Network Pharmacology; Neutropenia; Neutrophils; Piperidones; Quinazolinones | 2021 |